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Background: Aging process may result in immune modifications that lead to disruption of innate and acquired
immunity mechanisms that may induce chronic-degenerative events. The heat shock proteins (Hsp), phylogeneticaly
conserved among organisms, present as main function the ability of folding and refolding proteins, but they also are
associated with chronic-degenerative disorders. Here were evaluated the role of M. leprae native Hsp65 (WT) and its
point-mutated (K409A) on survival and anti-DNA and anti-Hsp65 antibody production of aged genetically selected mice
for high (HIII) and low (LIII) antibody production; data from 120- and 270-days old mice (named “adult” or “aged”,
respectively) were compared.
Results: WT Hsp65 administration induces reduction in the mean survival time of adult and aged female HIII mice, this
effect being stronger in aged individuals. Surprisingly, the native protein administration increased the survival of aged
female LIII when compared to K
409A and control groups. No survival differences were observed in aged male mice after
Hsp65 proteins inoculation. We observed increase in IgG1 anti-Hsp65 in WT and K409A aged HIII female mice groups
and no marked changes in the anti-DNA (adult and aged HIII) and anti-Hsp65 IgG1 or IgG2a isotypes production in
adult HIII female and aged male mice. LIII male mice presented increased anti-DNA and anti-Hsp65 IgG2a isotype
production after WT or K409A injection, and LIII female groups showed no alterations.
Conclusions: The results revealed that the WT Hsp65 interferes with survival of aged HIII female mice without
involvement of a remarkable IgG1 and IgG2a anti-DNA and anti-Hsp65 antibodies production. The deleterious effects of
Hsp65 on survival time in aged HIII female mice could be linked to a gender-effect and are in agreement with those
previously reported in lupus-prone mice.
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Aging is defined as progressive alterations of biological
functions, leading to the onset of diseases and reduced
ability to respond to external stimuli [1]. Alongside with
the physiological aging events, the immunosenescence ac-
cumulates potential modifications in immunological func-
tions and its components. The most important changes
include the decrease of the absolute number of lympho-
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unless otherwise stated.increasing of serum levels of immunoglobulin (mainly IgA
and IgG), limitation of the protective response of specific
high affinity antibody, amplification of autoantibody pro-
duction and a switch for a Th2 pattern of cytokine re-
sponse [2]. The altered processes in advanced age also
result in the failure of self and non-self discrimination [3]
and disruption of the innate and acquired immunity
mechanisms, which may result in chronic-degenerative
events and subsequent loss of life quality [4-7]. Altogether,
these modifications lead to an increased vulnerability to
infections [8,9], reduced response to vaccines [10], devel-
opment of tumors [11,12], and autoimmune or inflamma-
tory diseases [13,14]. In addition, disorders related to theLtd. This is an Open Access article distributed under the terms of the Creative
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proteins typically linked to biological properties of the heat
shock proteins (Hsp) are reported [15,16].
Drastic alterations in physiological responses to stressful
events are related to Hsp production [17-19]. Hsp are phy-
logeneticaly conserved molecules among evolutionary scale
[20,21] which assist misfolding molecules and control the
arising of toxic protein aggregates, supporting the folding
and unfolding of polypeptides for degradation by proteo-
lytic machinery [22,23]. Hsp65, the most abundant and im-
munogenic protein of mycobacteria [24], is considered a
toxin and dominant antigen in infectious diseases, capable
of induce humoral and cellular immune responses [25-27].
Reports evidenced the immunodominant role of the Hsp60
family in infectious processes [28], besides of the role
played in inflammatory processes such as arthritis, type I
diabetes, multiple sclerosis and atherosclerosis [29-32]. In
the opposite, some studies demonstrate its regulatory func-
tion on immune suppression in rheumatoid arthritis [33]
and type I diabetes [34].
Previously, our group evaluated the immunomodulatory
effects in vivo of M. leprae Hsp65 on genetically homoge-
neous (NZBxNZW)F1 hybrid female mice that develop
systemic lupus erythematosus (SLE); the results showed
that the native protein (WT) aggravates the lupus progres-
sion in mice [35]. On the other hand, the K409A, a point-
mutated Hsp65 [36], revealed a potential in mitigating
lupus aggravation in these mice [37]. Hsp65 administra-
tion also increased eye lesions in mice susceptible to the
development of autoimmune uveitis [38].
Autoimmune diseases are more frequent in aged and in
female individuals [39] and thus we asked whether Hsp65
interference in autoimmunity is age and/or gender-related.
Reports of Hsp65 interference in autoimmunity and other
biological alterations occurring during the immunosenes-
cence process are related to gender and aging [40]. These
findings lead us to investigate whether M. leprae Hsp65 is
also involved in alterations of aged individuals, as the
immunosenescence process can lead to the onset of auto-
immunity. It was assessed the role played by passive admin-
istrations of WT and mutant K409A Hsp65 on the lifespan
and antibody production of aged HIII and LIII mice. We
conclude that the WT protein administration interferes
with the survival of aged and adults HIII female mice, even
though the anti-DNA and anti-Hsp65 antibody production
was not markedly changed. As no significant changes in
male mice survival and antibodies production were ob-
served we conclude that Hsp65 effects were gender-related.
Results
WT Hsp65 administration reduces the lifespan of HIII
female mice
Male and female two hundred-seventy-days old (aged)
mice were inoculated intraperitonially with a single doseof 2.5 μg/animal of WT or K409A Hsp65 in 0.2 mL of
PBS, or only PBS as control group. Mice were observed
until death for mean survival time (MST) and environ-
mental variance (VE) determination (Table 1). Figure 1A
illustrates the survival reduction of aged HIII female mice
inoculated with the native protein (308 ± 25 days, p <
0.01) compared to controls (530 ± 123 days). Also it was
observed a decrease of 24-fold in the WT group pheno-
typic variance (VE = 635 days in WT group versus VE =
15293 days in control group). Conversely, Figure 1B
shows that aged LIII females inoculated with WT Hsp65
presented higher MST (615 ± 46 days; p < 0.01) com-
pared to K409A (442 ± 97 days) and control group (441 ±
72 days) and a decrease in VE (2180 days) in contrast with
control (5328 days) and K409A (9590 days) groups. No sur-
vival differences were observed in aged male mice from
both HIII and LIII in all experimental groups (Figure 1C
and D).
Since the lifespan of aged HIII females (270-days old)
was shortened after WT Hsp65 inoculation, we asked
whether the same effect could be observed in adult HIII fe-
male mice (120-days old) injected with Hsp65 (Figure 2).
Adult HIII female mice showed a MST reduction after WT
protein administration (466 ± 134 days; p < 0.01) when
compared to K409A injected group (665 ± 37 days). The
first death occurred 247 days after inoculation of the na-
tive molecule, and the environmental variance was lower
in mutant- (1422 days, 22-fold less) and WT-inoculated
animals (18181 days, about 2-fold less) compared to con-
trol group (31473 days).
It is noteworthy that in mice from both lines and ages
no weight loss, piloerection or ascites were detected.
Anti-DNA and anti-Hsp65 antibody production are altered
after WT Hsp65 injection
Since the antibody production against heat shock proteins
are involved in autoimmune processes, we measured the
anti-DNA and anti-Hsp65 IgG1 and IgG2a isotypes pro-
duction after WT and point-mutated Hsp65 inoculation.
In aged HIII female mice, WT and K
409A inoculation
caused a 4.5-fold increase in anti-Hsp65 IgG1 production
(p < 0.01) (Figure 3A), compared to pre-immune animals
(zero days), at fourteen and seven days post-inoculation,
respectively. Despite the reduction observed in IgG2a
anti-Hsp65 (Figure 3A) and IgG1 anti-DNA (Figure 3B)
observed in aged HIII female mice, the non-inoculated
group (control) also showed this decrease, possibly indi-
cating an environmental interference non-related with the
protein injection. No differences in IgG2a anti-DNA pro-
duction were observed.
Antibody production kinetics analysis of aged HIII fe-
male mice shows an increase of the IgG1 anti-Hsp65 (p <
0.01) in the WT-injected group, starting at 2.8 log2 and
reaching 5.4 log2 on day fourteen, and 3.3 log2 to 6 log2 in
Table 1 Mean survival time (days) and environmental variance of HIII and LIII mice
♀ HIII adult ♀ HIII aged ♀ LIII aged ♂ HIII aged ♂ LIII aged
Control MST 614 ± 177 531 ± 123 442 ± 72 469 ± 84 575 ± 97
VE 31473 15294 5329 7141 9534
(n = 4) (n = 6) (n = 5) (n = 6) (n = 7)
WT MST 466 ± 134* 308 ± 25** 615 ± 46** 403 ± 88 463 ± 141
VE 18182 635 2180 7802 20018
(n = 4) (n = 6) (n = 5) (n = 8) (n = 8)
K409A MST 665 ± 37 492 ± 61 442 ± 97 537 ± 151 496 ± 134
VE 1422 3823 9591 23097 18093
(n = 4) (n = 5) (n = 5) (n = 7) (n = 8)
Mean survival time (MST) and environmental variance (VE) are shown for control, WT (native Hsp65) and K
409A (mutant K409A Hsp65) injected mice groups, males
(♂) and females (♀). The values are displayed as plus/minus standard deviation. The number of subject used for each treatment is indicated in parenthesis.
*p < 0.05 and **p < 0.01 related to the control of each mice group.
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when compared to pre-immune serum (data not shown).
In adult HIII female mice, the administration of both
WT and K409A Hsp65 molecules did not promote alter-
ations in the anti-Hsp65 antibody production kinetics
between all experimental groups until 33 days post-
inoculation (Figure 4A). However, the anti-DNA titer
was increased at 33rd days in WT (p < 0.01) and K409AFigure 1 Mean survival time of aged mice inoculated with Hsp65 pro
were intraperitoneally injected with 2.5 μg/animal of WT or K409A with 270
(log rank test Mantel-Cox). The control group was used as reference for sta(p < 0.05) groups (Figure 4B). Regarding aged HIII male
mice, the isotypes titration showed only increased IgG1
anti-Hsp65 isotype production compared to pre-immune
groups at the 14th day after the K409A Hsp65 injection
(data not shown).
After the observation of the increased survival of
aged LIII female mice injected with WT Hsp65, we in-
vestigated the effects of those molecules over theteins. Female HIII (A) and LIII (B), and male HIII (C) and LIII (D) animals
-days old (dotted line); whereas control mice received PBS. **p < 0.01
tistical analysis.
Figure 2 WT Hsp65 protein influences on survival of adult HIII
female mice. Female adults mice were intraperitoneally inoculated
with 2.5 μg/animal of WT, K409A proteins, or PBS (control group) at
120-days old (dotted line). *p < 0.05 (log rank test Mantel-Cox). The
control group was used as reference for the statistical analysis.
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No differences were observed in IgG1 (titers range
from 3.7 ± 0.8 to 4.2 ± 0.5 log2) and IgG2a (from 5.5 ±
0.8 to 7.0 ± 1.0 log2) anti-Hsp65 or IgG1 (from 2.0 ± 0.4
log2 to 2.5 ± 0.8 log2) and IgG2a (from 2.4 ± 0.5 log2 toFigure 3 Anti-Hsp65 and anti-DNA antibodies production in aged HIII
IgG2a (B) isotype production in the serum of aged mice (3–6 animals/grou
were set by ELISA before (day 0) and after 7 and 14 days post Hsp65 inocu
comparisons post-test).4.0 ± 1.9 log2) anti-DNA production in aged LIII female
mice after WT or K409A Hsp65 inoculation (Figure 5A
and B). On the other hand, LIII male mice showed ele-
vated levels of IgG2a anti-Hsp65 after 14 days subse-
quently the WT (p < 0.001) or K409A (p < 0.05) injection
(Figure 5C), whereas the anti-DNA data displayed mainly
an increase in IgG2a anti-Hsp65 after WT (p < 0.001) and
K409A (p < 0.01) inoculation (Figure 5D).
Discussion
Immunological functions may change with aging and
lead to a deficient immune response to several infections
and vaccines, predisposing the individual to chronic-
degenerative processes by the decline of self-tolerance
maintenance and loss of tissue integrity, directing to crypt
antigens release, amplified bystander activation and mo-
lecular mimicry events [2,41,42]. Based on the immune al-
terations observed in the aging process, the reports of
higher incidence of chronic-degenerative processes in el-
ders [14,43] and the deleterious effect of M. leprae Hsp65
administration on murine lupus and autoimmune uveitis
[35,38], we evaluated the interference of WT Hsp65 ad-
ministration on survival time and correlation with anti-
body production in HIII and LIII mice. The animals fromfemale mice. Anti-Hsp65 IgG1 and IgG2a (A), and anti-DNA IgG1 and
p) inoculated with WT, K409A Hsp65, or PBS (control). Antibody titers
lation. *p < 0.05 and **p < 0.01 (Two-way ANOVA, Bonferroni multiple
Figure 4 Anti-Hsp65 and anti-DNA antibodies production in adult HIII female mice. Anti-Hsp65 IgG1 and IgG2a (A), and anti-DNA IgG1 and
IgG2a (B) isotype production in the serum of adult HIII female mice (4 animals/group) inoculated with WT, K
409A Hsp65, or PBS (control). Antibody
titers were determined by ELISA before (day 0) and after 13 and 33 days post Hsp65 inoculation. *p < 0.05 and **p < 0.01 (Two-way ANOVA,
Bonferroni multiple comparisons post-test).
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the humoral immune response and its influences over the
susceptibility to infections [44], autoimmunity [45] and
tumorigenesis [46]; they also differ in the response to anti-
gens not related to those used for the selection procedure
[47] and present different susceptibility to autoimmune
disease [48]. Moreover, HIII and LIII mice are used to verify
the influence of genetic alterations over longevity, as dem-
onstrated by the differences between the survival of dis-
tinct genetic bidirectional selections: Selection I and II
presents different survival between lines and gender and
Selection III shows similar mean survival time regardless
of sex or linage (HIII: 611 ± 153 days, LIII: 622 ± 166 days)
[49,50].
Native Hsp65 effects on survival of aged and adults HIII
female mice indicate the immunological interference of the
Hsp65 molecule in this model. It reduced the survival of
HIII female mice, mainly in young aged (270-days old), with
first death occurring 18 days after WT administration,
whereas for adults HIII female mice (120-days old) it oc-
curred 247 days post-injection, a period 14-times greater
than the aged mice. In opposition, WT-inoculated aged LIII
female mice presented higher MST (615 ± 46 days, p <
0.01) compared to mutant and control groups (442 ± 97and 441 ± 72 days, respectively). Despite the differences of
the maximal survival time in control groups (Additional
file 1), we can take these data in account as the maximal
survival obtained was within to those previously observed
[50], with 501 days in aged LIII female and 759 days in aged
LIII male mice. The maximal survival of control group of
HIII female (763 and 765 days) or LIII male (759 days)
showed a significant difference because some mice died
with extreme lifespan. Despite the low number of animals
used (restricted by the ethics committee) the results dem-
onstrated that the M. leprae Hsp65 injection could alter
the survival, reducing MST in HIII and augmenting in LIII
female mice.
Considering that LIII line shows an 18-fold reduction in
the antibody production and low T cell proliferation [51],
it is possible to consider that the humoral response of LIII
mice against Hsp65 is reduced, resulting in an easy man-
agement by the system to return to homeostasis. The
same could be true for other mice lines with lower anti-
body response compared to HIII mice, like Swiss albino
mice (foundation of Selection III lines) [47]. Contrary, the
high responder rate of the immunological system in HIII
female mice after WT injection, despite the antibody pro-
duction rate, could disrupt the homeostasis and lead to a
Figure 5 Anti-Hsp65 and anti-DNA antibodies production in aged LIII mice. Anti-Hsp65 IgG1 and IgG2a (A and C) and anti-DNA IgG1 and
IgG2a (B and D) isotype production in the serum of aged LIII mice (4–8 animals/group, males and females) inoculated with WT, K
409A Hsp65, or
PBS (control). Antibody titers were determined by ELISA before (day 0) and after 7 and 14 days post-WT or -K409A Hsp65 inoculation. *p < 0.05,
**p < 0.01 and ***p < 0.001 (Two-way ANOVA, Bonferroni multiple comparisons post-test).
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process in association with the interference of Hsp65 in-
oculation could explain the higher decrease in survival of
HIII aged female. In spite of our animal model do not
spontaneously develop autoimmune processes, the re-
duced survival time of HIII female mice matches to the ex-
periments involving lupus-prone mice [35] and models of
experimental autoimmune uveitis in mice [38], and re-
assure the involvement of Hsp in chronic-degenerative pro-
cesses. The control expression and the rupture of Hsp65
balance in SLE development were ascertained through the
approach of inductive disequilibrium of physiological and
immune states by homologous Hsp [52] and the same
could be true for the current study.
Since High and Low mice lines differ, respectively, to
high or low antibody responses, the anti-DNA and anti-
Hsp65 IgG isotypes production were analyzed after WT
or K409A Hsp65 inoculation. HIII and LIII mice, both
genders, presented slightly higher production of IgG2a
anti-Hsp65 and anti-DNA related to the IgG1 isotype.
This balance towards a Th1 response may indicate a nat-
ural pro-inflammatory status in these strains which is
confirmed by the relative easy way to induce adjuvant
arthritis in HIII mice [53]. The time-course analyses of
immunoglobulin production did not show significantintragroup differences, which might be related to the ab-
sence of a strong specific response to these proteins
demonstrated by the low antibody titers even 30 days
after the protein inoculation and because this is not an
immunization process. Compared to pre-immune mice,
aged HIII females presented an increase of anti-Hsp65
IgG1 in the group treated with WT or K409A Hsp65 and
a non-related reduction of IgG2a. In murines, the IgG1
and IgG2a functions are dependent on the cells activa-
tion threshold determined by the affinity of antibodies
and the expression of inhibitors/activators receptors
[54]. The amplification of anti-Hsp65 IgG1 antibody (ap-
proximately 4-times) should be related with a switch to a
Th2 response, previously observed in the immunosenes-
cence process [2]. It also could correlate to the precocious
death of aged HIII female mice, since the augment of Th2
cytokines, despite its regulatory effect, are involved in
some diseases like asthma, allergies and autoimmunities
[55,56].
Confirmed the M. leprae Hsp65 effect on reduced sur-
vival in aged HIII female mice, it was evaluated whether the
anti-DNA and anti-Hsp65 antibody production were age-
dependent by comparing the IgG isotypes with adults HIII
female mice. They did not present intergroup changes in
kinetics of anti-DNA or anti-Hsp65 antibodies production,
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after Hsp65 molecules injection. The IgG2a isotype titers
are remarkably lower in adult mice compared to aged ones
as an indicative of a better balance of Th1/Th2 response
and maintaining homeostasis of the immune system, as
demonstrated by the 13-times later death in adult HIII fe-
males after WT inoculation compared to old mice.
This dominating effect observed in the survival time of
aged mice emphasizes the involvement of the Hsp65 mol-
ecule in aging processes. The effect of native molecule was
gender-specific, as demonstrated by the unaltered MST in
aged male mice (HIII and LIII) inoculated with both pro-
teins, and potentially related with the differential regulation
of the immunological system by sexual hormones [57], as
the dimorphism between gender is positively linked with
different susceptibility for infections, autoimmune diseases
and tumor incidence [40,58]. Sexual hormones (mostly es-
trogen but also progesterone and testosterone) affect im-
mune cells quantitatively and qualitatively and impact on
cytokine production [59]. Females have higher plasma con-
centrations of immunoglobulin, increased number and
strong activation of CD4+ T cells, elevated levels of Th1 cy-
tokines (IgG2a production) and stronger primary and sec-
ondary antibody response [60,61]. Indeed, the higher
incidence of SLE in females reflects the gender dimorph-
ism [62,63].
It should also be considered the animal model used to
test the relationship of Hsp and aging. The opposite phe-
notypes of antibody production in HIII and LIII mice in-
clude immune response to a wide range of antigens [47].
The F0 - foundation population - of Selection III mice are
genetically heterogeneous: the phenotypic variance (VP) is
due to the sum of the genetic variance (VG), and the envir-
onmental variance (VE) emerges by all the causes of vari-
ability resulting from the environment. The bi-directional
selection resulted in a progressive increase (HIII mice) or a
decrease (LIII mice) in mean antibody response, followed
by the decline of VG in both lines [47,64]. Therefore, the
alterations provoked by WT or K409A Hsp65 administra-
tion (the environmental feature applied during the experi-
ments) provide the variance in our experimental model.
After WT inoculation, a great reduction in variance value
was observed in aged female HIII (VE = 635 versus VE =
15293 of the control group) than LIII mice (VE = 2180
versus VE controls = 5328), showing the impact of this
molecule administration over the potential of death
phenotype (MST = 308 ± 25 in aged HIII and MST =
615 ± 46 in aged LIII female mice). We cannot exclude
the interference of others genetic factors occurred during
the selective breeding, and a gender-effect that may affect
the response in HIII and LIII mice. Since it was proposed
that the presence of anti-Hsp60 autoantibodies, innate risk
factor of atherosclerosis in adulthood, may be an inherited
trait, we are conducting studies about the effect of Hsp65in (HIIIxLIII)F1 hybrids to clarify the genetic influence of
this susceptibility [65].
Mechanisms underlying the distinct effects of the native
Hsp65 on survival of HIII and LIII mice, and the comparison
between them and mutant injected individuals are under
evaluation. Preliminary histopathological analysis with some
control- and WT-injected HIII female mice (3 animals/
group) indicates that the WT Hsp65 inoculation results in
a widespread chronic hepatitis, spleen hyperplasia, and, un-
like LIII female, higher degree of nephrosis and chronic
nephritis with inflammatory infiltration of plasma cells,
macrophages and lymphocytes (data not shown), character-
istics also present in human lupus nephritis [66]. Studies of
immune cells alterations in spleen and blood samples of
aged HIII female mice injected with M. leprae Hsp65 are in
progress. The initial results shows increased splenic B cells
percentage, amplified expression of CD45RA and CD154 in
CD4+ T cells, reflecting on the augmented anti-Hsp65 IgG1
isotype production observed here, and amplified surface ex-
pression of CD11b and CD11c in blood monocytes.
The adaptive management of biological systems accord-
ing to environmental changes is essential for the organism
survival and Hsp molecules can interfere with immune
phenotypes submitted to independent polygenic control.
The aging process presents an impaired cellular homeo-
stasis and the Hsp presentation by antigen presenting cells
may be diminished, being responsible for the decline in
immunoregulation through the recognizing of self Hsp
[67]. On the other hand, an amplified expression of stress
proteins and his antigenic determinants can evolve to a
pathogenic or regulation of chronic-degenerative pro-
cesses [68-70]. Taking together, these facts explain the
pleiotropic effects of Hsp65 on biological systems and its
wide actions over different cell types and production of
other molecules. Based on pleiotropy, the Theory of Aging
proposed by George C. Williams suggests that some genes
responsible for increased fitness in young fertile individ-
uals may contribute to the reduction of such capacity in
later life [71]. Then, it is conceivable that selection for high
antibody production genes, essential for the immune pro-
tection through the life of an individual, can be one of the
factors that allows Hsp65 act on the immune or physio-
logical imbalance later in life. As previously reported by
our group, the WT Hsp65 passive administration affects
the endogenous balance by increase the entropy of the in-
dividual system; the linear equation proposed (y = a +Δi)
shows that the immunological history (y) is unique, irre-
versible and cumulative [35]. In this study, the animal
model employed is not naturally predisposed to auto-
immunity, so “a” should include the potential advent of
chronic-degenerative processes in aging and “i” consists
by the sum of the environmental factors that modulate the
entropy: age, gender, antibody production rate, and pos-
sible cellular and molecular alterations established in
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ments interfere in how Hsp65 interact with the immune
system; consequently, the greater their influence, greater
the entropic energy, hindering the recovery of homeostasis
and contributing to the deaths of HIII female mice.
Despite the absence of strikingly differences in anti-
body production in our experiments, perhaps the 2-fold
higher antibodies production in HIII females compared
to males [47], associated with the senescent immune sys-
tem and influenced by hormones, are sufficient to in-
duce frailty after WT administration. In parallel, the high
antibodies production rate in HIII, besides increasing the
system entropy, can result in reduced antibody affinity
for the protein, facilitating its subsequent binding to
self-antigens. In case of imbalance due to the overstimu-
lation by stress or inflammation, autoimmune diseases
may emerge or aggravate [35,52]. The opposed occurs in
LIII females, which presented increased survival when
injected with the native molecule, suggesting that the
low immunoglobulin production may favor the control
of immune system overstimulation.
We do not observed any signs of disease development
during the survival time assay and this be correlated
with the incapacity of the mycobacterial Hsp65 alone to
induce, in some cases, autoimmunity. In an experiment
of arthritis induction by Complete Freund’s adjuvant
(CFA) replaced with the whole mycobacterium [72], the
intradermal injection induced arthritic lesions at the same
degree as CFA in ankle joints, with the production of anti-
DNA and anti-Hsp65 in rats. Thus, the not remarkable in-
crease of anti-Hsp65 antibodies presented by HIII and LIII
mice may be responsible for the absence of disease.
More than a phenotypic effect by the antibody produc-
tion against WT Hsp65, the extended pleiotropic effect of
this protein over the immune system results in strength-
ening of naturally established disorders in aged HIII female
mice who possibly present a natural higher degree of en-
tropy. In addition, the age-remodeled immune system
already shows a major entropy level and the injection of
M. leprae WT Hsp65 in females reinforce an imbalance
that does not resemble the young individuals, originating
disorganizations and irreversible processes leading to
death.
Conclusions
Here we verified in an aging mice model the role of M.
leprae Hsp65 in the aggravation of phenotypes, as ob-
served in SLE and experimental autoimmune uveitis,
and outlined its interference mainly in aged HIII female
inducing precocious death. We assume that this effect is
associated to the aging process and related to gender-
effect instead of the amount of antibody produced in
these mice lines. Studies of cellular and cytokines alter-
ations after the Hsp65 administration in Selection IIImice and its (HIIIxLIII)F1 hybrid mice are in progress to
elucidate the mechanisms by which this heat shock pro-
tein and its responses act in the immune system of aged
individuals.
Methods
Expression of the recombinants M. leprae Hsp65 in
Escherichia coli and purification
Clone pIL161, containing the coding sequence of the M.
leprae WT Hsp65 and its point-mutated form K409A [36]
were amplified in E. coli DH5a cells. Expression and purifi-
cation of the recombinant Hsp65 WT and K409A was de-
scribed elsewhere [35].
Animals
The genetically heterogeneous selected mice for High
(HIII) or Low (LIII) antibody production were bred in the
animal facility of the Immunogenetic Laboratory and
maintained at the animal facility of the Immunochemistry
Laboratory, both in Butantan Institute. They were housed
in groups of four to five in plastic cages filled with hard-
wood bedding, provided with water and rodent chow ad
libitum, in a room with 12-h light/dark cycle, controlled
pressure, humidity and temperature (24 ± 2°C). All proce-
dures are in agreement to the International Animal Wel-
fare Recommendations [73] and the experiments are in
conformity with the Ethical Principles in Animal Research,
adopted by the Brazilian College of Animal Experimenta-
tion, and was approved by the Ethical Committee for Ani-
mal Research of Butantan Institute (CEUAIB #475/08).
Administration of the WT and K409A Hsp65 molecules
Male and female HIII and LIII mice at the age of 120- or
270-days old (named here “adult” or “aged” mice, re-
spectively) were inoculated intraperitonially with a single
dose of 2.5 μg of WT or K409A Hsp65 of M. leprae in
0.2 mL of phosphate buffer saline pH 7.4 (PBS); as con-
trols, mice were injected with 0.2 mL PBS. In this study it
is important to highlight that the periodically bleedings
were performed at different time points in aged and adult
female mice; from previously observations that aged HIII
female animals death started 18 days after the WT Hsp65
administration (bleedings occurred at seven and at four-
teen days post proteins administration). Differently, adult
HIII female individuals, which presented an extended sur-
vival time after the WT Hsp65 inoculation, were bled
after fourteen and thirty-three days after the proteins in-
jection; this longer interval was used to avoid external
stress stimuli that could influence the experiment. The
serum samples were stored at −20°C until antibody titra-
tion. Each animal was observed until death for the de-
signing of the longevity curve and examined for clinical
signs that include development of ascites and lethargy.
Baldon et al. Immunity & Ageing 2014, 11:6 Page 9 of 10
http://www.immunityageing.com/content/11/1/6Titration of anti-DNA and anti-Hsp65 antibodies
Levels of anti-DNA and anti-Hsp65 IgG1 and IgG2a iso-
types titers were set by indirect ELISA as describe before
[35] and expressed as log2 of the reciprocal serum dilution
giving an absorbance value of 20% of the saturation level.
Statistical analyses
All statistical analyses were performed with GraphPad
Prism 5.0 software. The antibody dosages are expressed as
mean ± SD. Two-way ANOVA with Bonferroni multiple
comparisons post-test were used to evaluate the antibody
production between mice from control, WT and K409A
groups. Kaplan-Meier plot for mean survival time (MST)
was analyzed by log-rank test (Mantel-Cox) comparing
the MST with age, dose or administration period of WT
or K409A rHsp65. For all data, minimum statistical signifi-
cance was set at p<0.05.
Additional file
Additional file 1: Percent survival of control groups in Selection III
mice. HIII and LIII from control group, used in survival analysis, were
compared. The adults (270-days old) and young aged (120-days old)
female HIII mice where analyzed together. Those mice received PBS (200 μL/
animal) at 120- or 270-days as previously described. Statistical analysis (log rank
test (Mantel-Cox)): ap < 0.05 HIII male versus HIII female;
bp < 0.05 HIII male
versus LIII male;
cp < 0.05 HIII female versus LIII female and
dp < 0.01 LIII female
versus LIII male.
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